Multiple_Myeloma_International_Staging_System v.1
Multiple Myeloma International Staging System (ISS) prognosticates the severity of multiple myeloma based on routinely obtained lab values.
To prognosticate the severity of multiple myeloma based on serum β2 microglobulin and albumin levels.
Use to prognosticate the severity of multiple myeloma based on serum β2 microglobulin and albumin levels. The ISS differentiates patients into 3 separate prognostic groups: Stage Criteria I Serum β2 microglobulin <3.5 mg/L AND serum albumin ≥ 3.5 g/dL II Either: serum β2 microglobulin <3.5 mg/L, but serum albumin <3.5 g/dL OR serum β2 microglobulin 3.5 – 5.4 mg/L irrespective of the serum albumin III Serum β2 microglobulin ≥5.5 mg/L
Not to be used in patients with relapsed myeloma, smoldering myeloma or MGUS.
1. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842-54. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. PMID: 1182674. 2. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242. Epub 2005 Apr 4. Erratum in: J Clin Oncol. 2005 Sep 1;23(25):6281. Harousseau, Jean-Luc [corrected to Avet-Loiseau, Herve]. PMID: 15809451.
EVALUATION.multiple_myeloma_iss_assessment.v0, OBSERVATION.lab_test_serum_b2_microglobulin.v0, OBSERVATION.laboratory_test_result-serum_albumin.v0
